{"id":"naropin-0-1-cum-sufentanil","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL1201163","moleculeType":"Small molecule","molecularWeight":"578.68"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Ropivacaine reversibly inhibits sodium influx in nerve fibers, preventing depolarization and action potential propagation, thereby producing local anesthesia. Sufentanil, a potent synthetic opioid, binds to mu-opioid receptors in the central and peripheral nervous system to provide additional analgesia and enhance the overall pain-relieving effect of the combination.","oneSentence":"Naropin (ropivacaine) is a local anesthetic that blocks sodium channels in nerve membranes, while sufentanil is an opioid agonist that enhances analgesia through mu-receptor activation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:37.226Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Regional anesthesia and analgesia (epidural or peripheral nerve block)"},{"name":"Postoperative pain management"}]},"trialDetails":[{"nctId":"NCT01025102","phase":"PHASE3","title":"The Addition of Sufentanil Interscalene Block in Shoulder Surgery","status":"COMPLETED","sponsor":"Bent Gymoese Jorgensen","startDate":"2010-01","conditions":"Postoperative Pain, Shoulder Surgery","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Local analgetic","Ropivacain"],"phase":"phase_3","status":"active","brandName":"Naropin 0.1% cum sufentanil","genericName":"Naropin 0.1% cum sufentanil","companyName":"Bent Gymoese Jorgensen","companyId":"bent-gymoese-jorgensen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Naropin (ropivacaine) is a local anesthetic that blocks sodium channels in nerve membranes, while sufentanil is an opioid agonist that enhances analgesia through mu-receptor activation. Used for Regional anesthesia and analgesia (epidural or peripheral nerve block), Postoperative pain management.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}